The next generation of intestinal microbes
A-Mansia is a Belgian microbiome spinoff company based on discoveries made by the founding scientists Prof. Willem M. de Vos (Wageningen University -The Netherlands) & Prof. Patrice D. Cani (UCLouvain – Belgium)
In 2004, Akkermansia muciniphila MucT (Akkermansia) was isolated from human gut by Pr. W.M. de Vos team’s – Laboratory of Microbiology, Wageningen University & Research Center, Netherlands1.
Then, Pr. P.D. Cani team’s – UCLouvain, Metabolism and Nutrition Research Group, LDRI, Belgium – discovered that murine models of obesity and/or type 2 diabetes were characterized by a lower abundance of Akkermansia. In addition, they found strong correlations between the presence of Akkermansia and lower cardiometabolic risk factors2.
Both researchers decided to collaborate in order to produce this anaerobic bacterium for preclinical investigations and decipher its potential health effects on preclinical models.
Besides the numerous correlations observed, this collaboration led to several scientific articles demonstrating (i) a large body of evidence of the causal beneficial impact of this bacterium in a variety of preclinical models, (ii) the ability to produce a bacteria compatible and safe for human use³ and (iii) accomplished the first proof-of-concept study using Akkermansia in humans4.
It’s against that stimulating background with strong scientific evidences and know how that the A-mansia company was borned.